Implement Liquid Biopsy Technology Across the Full Trial Lifecycle, from Sharpening Patient Selection to Tracking Response & Recurrence, to Reach Decisions Faster & Spend Less Getting There
Liquid biopsy remains one of the largest investments in oncology drug development. If your clinical program is not acting on every signal it generates, you could be leaving significant value and budget, on the table.
The 11th Liquid Biopsy for Precision Oncology Summit West Coast will spotlight how industry-leading teams are closing that gap, from first-in-human dose finding to MRD endpoints, resistance monitoring and patient access.
The field is evolving faster than ever; in the last year, SERENA-6 and IMvigor011 have transformed how sponsors design trials, assays have become increasingly sensitive and specific, and the vendor landscape is consolidating. Fail to keep pace with these advancements and your ctDNA strategy risks already being out of date.
Take your place alongside AstraZeneca, Genentech, Amgen, Pfizer, Johnson & Johnson, Regeneron, AbbVie, Takeda and more across two focused tracks of live program data, panels and one-to-one meetings, and leave knowing exactly what to change on Monday.
-
I look forward to engaging with my colleagues in the field and discussing how we can leverage liquid biopsies to address current limitations in diagnostic testing and advance precision oncology
Head, Diagnostics, Amgen, 2027 Speaker
-
I am looking forward to developing relationships that can recognize the need for rare disease testing access
Head, US Diagnostics, Alexion Pharmaceuticals, 2027 Speaker
-
I thought it was great to interact with the leading pharmaceutical and biotech companies and discover advanced upfront technologies. The meeting also boasted great networking
Biomarker Program, Precision Medicine Operations & Portfolio Strategy Manager, AbbVie, Past Attendee
-
The size of the meeting was just right allowing meaningful interactions and networking. The agenda content was rich and informative
Head, Translational Research, Zai Lab, Past Attendee
-
The event provided very informative presentations and engaging panel discussions
Board Director, TOLREMO Therapeutics, Past Attendee
-
I appreciated the extremely high quality and qualification of attendees
Vice President, Translational Data Science, Zentalis Pharmaceuticals, Past Attendee
Discover the Complete LBx Event Program
- Identify Your Sessions Fast: See exactly where dose optimization, MRD endpoints and resistance monitoring are covered, so you can plan your team around the decisions you face.
- Assign Each Team Member to a Track: With two content tracks running in parallel, make sure your team benefits from all the unmissable insights available.
- Preview Live Program Data: Get a first look at what AstraZeneca, Amgen, AbbVie, Johnson & Johnson and Kura Oncology are learning from ctDNA in their real-world trials.
- Act Before the Scan Does: Find out how teams are building on SERENA-6 to switch therapy on molecular progression, and what evidence this takes.
- Spot Where You Are Under-Using ctDNA: Benchmark your current assay choices and monitoring strategies against what the leading sponsors in the liquid biopsy space.
- Align Your Cross-Functional Teams: Pass on to colleagues who sign off on assays, partners and budgets so that your entire team are united on the cases for acting
Expertise Partners
Leading Biopharma Companies in Attendance
About the World Biomarkers & Diagnostics Event Series
The 11th Liquid Biopsy for Precision Oncology Summit West Coast is part of the wider World Biomarkers & Diagnostics Event Series, the trusted space for the global precision medicine community. Convening experts from biopharma, diagnostics, testing laboratories, and healthcare, this event portfolio collaboratively advances the future of biomarker and diagnostic-driven drug development.
Offering one place to share experiences, benchmark strategies, spotlight emerging technologies and build new connections, these meetings play a critical role in driving progress in precision medicine.
Be part of the industry's premier biomarkers and diagnostics event series and the conversations defining the next era of precision medicine.
Discover the Event Program
See where leading teams at AstraZeneca, Amgen, Pfizer and Johnson & Johnson are taking ctDNA next, from dose finding through to MRD endpoints.
Prioritize Partnering With Us
Place your liquid biopsy platform in front of the pharma teams choosing assay partners for their next trials, before the vendor landscape settles.
Join 250+ Biopharma Peers
Meet the translational and precision medicine experts shaping future liquid biopsy strategies, so you can return to your team with actionable plans to implement in 2027 and beyond.